Use of l-carnitine for the treatment of cardiovascular diesases
AssigneeSigma-Tau Industrie Farmaceutiche Riunite S.p.A.
InventorAleardo Koverech
Life of this patent
Estimating the term…
Loading patent…
AssigneeSigma-Tau Industrie Farmaceutiche Riunite S.p.A.
InventorAleardo Koverech
Estimating the term…
The use of L-carnitine, or one of its pharmaceutically acceptable salts, is described in combination with glucose for the preparation of a medicament useful for diminishing the number of deaths caused by acute myocardial infarction, for reducing the number of days infarction patients spend in intensive care in hospital, and for reducing the number of episodes of post-infarction heart failure, in which the L-carnitine is administered intravenously within only a few hours of the onset of symptoms of acute myocardial infarction at an initial dose of 9 grams a day in combination with 1000-1500 mL of a 5% glucose solution for 5 days, after which the L-carnitine treatment is continued at a dose of 4 grams a day administered orally.
A method for reducing the number of episodes of death caused by acute myocardial infarction in patients as compared to a control group treated with L-carnitine in saline comprising intravenously administering L-carnitine or one of its pharmaceutically acceptable salts within 6 hours of the onset of symptoms of acute myocardial infarction to patients in need thereof, at an initial dose of 9 grams a day, in combination with 1000-1500 ml of a 5% glucose solution for 5 days, followed by orally administering the L-carnitine or one of its pharmaceutically acceptable salts at a dose of 4 grams a day, whereby said number of episodes of death caused by acute myocardial infarction are reduced compared to said control group.
Dependencies are inferred from the claim text.